whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives

October 2009

Women are asking whether Yaz and Yasmin (drospirenone/ethinyl estradiol) are riskier than other combined oral contraceptives.

They're hearing about a stream of lawsuits against these drugs.

Lawyers are targeting Yaz and Yasmin partly due to FDA warnings about the company not adequately disclosing risks in consumer ads.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote